MOTS-c Side Effects, Withdrawal, and Discontinuation Syndrome: What the Evidence Actually Shows

Is there a MOTS-c withdrawal syndrome?

Whether stopping MOTS-c causes symptoms is unknown. Describing a withdrawal syndrome would require people to have been given the peptide and then followed after stopping it. FDA's July 2026 evaluation searched PubMed, Embase, the Cochrane library and other databases and found no clinical study in which MOTS-c was given to a human; the 12 papers the nominator submitted were not clinical studies [1]. FDA's adverse-event database searches through March 9, 2025 retrieved no MOTS-c reports [1].

That leaves no observed time course and no taper schedule that has been studied in people. Claims that MOTS-c can be stopped "safely" or "without consequence" have no human data behind them.

What has actually been reported as a side effect?

The concern FDA has stated for MOTS-c is about the injected product, not a list of observed reactions. On its page about bulk substances that may present significant safety risks when compounded, MOTS-c appears in the table of nominations withdrawn by their nominators. FDA's stated concerns were that it "has not identified any human exposure data on drug products containing MOTs-C administered via any route of administration", that important safety information is lacking, and that injectable peptides may pose immunogenicity risk because of aggregation and peptide-related impurities. FDA added that removal from category 2 was not a finding that the substance is safe [3]. MOTS-c has 16 amino acids, and no immunogenicity data exist [1].

Does injected MOTS-c stay in the body long enough to act?

How long injected MOTS-c remains in the human body is unknown. FDA found no pharmacokinetic data for MOTS-c in humans or in live animals. A laboratory study found the peptide is quickly broken down in human blood, which raises the question whether injecting it can produce active levels in people [1]. There is no approved dose and no human dosing study. The nominated products were 5 mg and 10 mg subcutaneous injections, and the rodent doses (0.5 to 15 mg/kg) cannot be converted into human doses [1].

Where the benefit claims come from

The metabolic and performance claims rest on mouse work. The 2015 discovery paper in Cell Metabolism reported a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA. In mice, MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance as well as diet-induced obesity, with skeletal muscle as the main target and AMPK activation as the cellular action [2].

A 2021 Nature Communications study found that MOTS-c enhanced physical performance in young, middle-aged and old mice, and that late-life intermittent treatment three times weekly from 23.5 months of age increased physical capacity and healthspan in mice. In humans, that study showed that exercise induces the body's own MOTS-c expression in skeletal muscle and in the circulation; participants were not given the peptide [6].

A 2021 randomized trial in the Journal of Applied Physiology assigned 30 healthy adults to endurance exercise (n=10), resistance exercise (n=10) or control (n=10). Humanin rose after endurance exercise, while MOTS-c showed only a trend to increase, and plasma peptide levels were not related to fitness [7]. None of this involved injected peptide in people, so none of it describes what happens when an injected peptide is stopped.

Regulatory status: not approved, not on the compounding lists

MOTS-c is not an FDA-approved drug and is not a component of one. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no product authorized by the European Medicines Agency [1]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) and is absent from the list for outsourcing facilities (updated March 21, 2025), so FDA's category 1 policy does not cover it [8][9][4].

FDA staff proposed that neither the free base nor the acetate be added to the compounding list. They cited no human safety or effectiveness data, no animal toxicity studies, and inconsistent naming with no impurity, aggregate or endotoxin data [1]. FDA's Pharmacy Compounding Advisory Committee reviewed MOTS-c on July 23, 2026 and voted in favor of adding it, against FDA staff's recommendation. That vote is advice only and is not binding, and adding the substance would take formal rulemaking [10][11].

HHS's draft enforcement-discretion policy, filed October 28, 2026, names MOTS-c (acetate, subcutaneous or intramuscular injection) among six peptides. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the policy's conditions are met [11][12]. The notice states that it does not establish any rights and is not binding on HHS or the public; it is neither an approval nor a listing [11].

For athletes, WADA names MOTS-c in section S4.4.1 among activators of AMP-activated protein kinase. It is prohibited at all times, in and out of competition, and it appears on the 2026 List (in force since January 1, 2026) and the 2027 List [5][13].

Bottom line

What exists is mouse data on weight, insulin sensitivity and physical capacity, a laboratory finding that the peptide breaks down quickly in human blood, and a regulatory record in which FDA notes the absence of human data [1][2][6].